Medicenna and Fondazione Melanoma Onlus Announce Presentation on NEOCYT Trial at ASCO 2026
Original article ↗ 🔒 Paywalled source — limited preview availableB.I.A.S. ANALYSIS
CENTER
LEFTCENTERRIGHT
Signal breakdown
Heuristic (v1/v3)
0.00 · CENTER
ML v2 (DistilBERT)
-0.253 · LEFT
Ensemble
-0.127 · CENTER
🏦 Source Intelligence
Rolling outlet bias
CENTER
avg -0.054
2,788 articles tracked
7-day bias trend
LcenterR
Article Excerpt
NEO-CYT is a randomized, multi-centre trial of neoadjuvant MDNA11 (before curative intent surgery) sponsored by the Fondazione Melanoma Onlus, and led by Professor Paolo A. Ascierto of the Istituto Nazionale Tumori Fondazione “G. Pascale”, a leading cancer centre in Europe TORONTO and HOUSTON, April 30, 2026 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or the...
Read full article at Montreal Gazette ↗
How we scored this article
WTF uses a two-tier system: every article gets a heuristic bias score from keyword analysis, and priority articles (high overlap across 3+ outlets or strong heuristic signal) get full LLM analysis from B.I.A.S. and V.E.R.I.F.Y.